Cannabis
PAOG Advances Nutraceutical Development From Its Cannabis Pharmaceutical Research
Sandusky, Ohio–(Newsfile Corp. – October 29, 2020) – PAO Group, Inc. (OTC Pink: PAOG) today announced adding a nutraceutical development pathway to its existing pharmaceutical cannabis drug development strategy. Last week, PAOG announced a master services agreement with a clinical research organization (CRO) in the U.S. to prepare PAOG for initiating an investigational New Drug application (IND) with the Food and Drug Administration (FDA). More details on the CRO contract are coming soon. Now PAOG has committed to simultaneously launching a nutraceutical development initiative drawing on its respiratory therapy cannabis extract treatment research. The nutraceutical development pathway is anticipated to rapidly progress PAOG to a revenue stream while continuing to pursue the pharmaceutical development pathway. PAOG anticipates soon announcing a nutraceutical development contract.
Separately, PAOG confirms plans with Puration, Inc. (OTC Pink: PURA) to publish a joint update tomorrow, Friday, October 30, 2020 on the progress toward making PURA shareholders PAOG shareholders. PAOG recently acquired PURA’s cannabis cultivation operation in a deal that included the issuance of PAOG stock to PURA shareholders in a dividend distribution. Management of the two companies will provide a progress update on the dividend process tomorrow.
Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward-looking statements to reflect events or circumstances after the date of this release.
CONTACT INFORMATION
Contact Us:
Jim DiPrima
888-272-6472
[email protected]
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/67126
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
Cannabis
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
Cannabis
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Cannabis2 weeks ago
Right on Brands Announces Major Product Line Expansion via HONEY® Brands
-
transfer2 weeks ago
IMC to transfer its Oranim Pharmacy shares back to the seller
-
Cannabis1 week ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis1 week ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
CCELL®2 weeks ago
CCELL Launches Environmentally Conscious Eco Star AIO Vaporizer
-
Innocan6 days ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf6 days ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis5 days ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care